



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003826 F 12/05/1988 34 Y

Referral Testing

Collected: 10/20/2023 11:56 Received: 10/20/2023 11:56

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: B. burgdorferi VlsE1/pepC10 Abs, CSF w Reflex, 6.50, H, <=0.90, IV, ARRL

REFERENCE INTERVAL: B. burgdorferi VlsE1/pepC10 Abs, CSF

- 0.90 IV or less Negative - VlsE1 and pepC10 antibodies to B. burgdorferi not detected.
0.91-1.09 IV Equivocal - Repeat testing in 10-14 days may be helpful.
1.10 IV or greater Positive - VlsE1 and pepC10 antibodies to B. burgdorferi detected.

The detection of antibodies to Borrelia burgdorferi in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier. Lyme disease diagnosis in serum is recommended prior to any CSF studies.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Performed By: ARUP Laboratories
500 Chipeta Way
Salt Lake City, UT 84108
Laboratory Director: Jonathan R. Genzen, MD, PhD
CLIA Number: 46D0523979

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: Borrelia burgdorferi Ab, IgM, IB (CSF), Positive, AB Negative, -1, ARRL

INTERPRETIVE INFORMATION: Borrelia burgdorferi Ab, IgM, IB (CSF)

For this assay, a positive result is reported when any 2 or more of the following bands are present: 23, 39, 41 kDa. All other banding patterns are reported as negative.

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003826 F 12/05/1988 34 Y

Referral Testing

Collected: 10/20/2023 11:56 Received: 10/20/2023 11:56

Test Name	Result	Flag	Ref-Ranges	Units	Site
	<p>The detection of antibodies to <i>Borrelia burgdorferi</i> in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.</p> <p>This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.</p>				

Borrelia burgdorferi Ab, IgG, IB (CSF)	Positive	AB	Negative	Reported Date: 2023.10.20 -:1	ARRL
--	-----------------	-----------	----------	----------------------------------	------

INTERPRETIVE INFORMATION: *Borrelia burgdorferi* Ab, IgG, IB (CSF)

For this assay, a positive result is reported when any 5 or more of the following 10 bands are present: 18, 23, 28, 30, 39, 41, 45, 58, 66, or 93 kDa. All other banding patterns are reported as negative.

The detection of antibodies to *Borrelia burgdorferi* in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Lyme Standard 2-Tier Testing, CSF Interp	Positive	AB	Negative	Reported Date: 2023.10.20 -:1	ARRL
--	-----------------	-----------	----------	----------------------------------	------

Both IgM and IgG-class antibodies to the *Borrelia* species causing Lyme disease were detected, suggesting recent or remote past infection.

If both first tier screen test and second tier tests are equivocal, consider repeat testing in 7-14 days if clinically warranted.

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F42000012
WX0000003826
Printed D&T: 10/20/23 11:58

Ordered By: KAJAL SITWALA, MD, PhD
WX0000000002353

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 2 OF 3



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003826 F 12/05/1988 34 Y

Referral Testing

Collected: 10/20/2023 11:56 Received: 10/20/2023 11:56

<u>Test Name</u>	<u>Result</u>	<u>Flag</u>	<u>Ref-Ranges</u>	<u>Units</u>	<u>Site</u>
	INTERPRETIVE INFORMATION: Lyme Standard 2-Tier, CSF, 2nd Tier				
	IgG: For this assay, a positive result is reported when any five or more of the following 10 bands are present: 18, 23, 28, 30, 39, 41, 45, 58, 66, or 93 kDa. All other banding patterns are reported as negative.				
	IgM: For this assay, a positive result is reported when any two or more of the following bands are present: 23, 39, or 41 kDa. All other banding patterns are reported as negative.				
	The detection of antibodies to Borrelia burgdorferi in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier. Lyme disease diagnosis in serum is recommended prior to any CSF studies.				
	This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.				
	Performed By: ARUP Laboratories 500 Chipeta Way Salt Lake City, UT 84108 Laboratory Director: Jonathan R. Genzen, MD, PhD CLIA Number: 46D0523979				

Reported Date: 2023.10.20 11:57 BBABC

Performing Site:

ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F420000012
WX0000003826

Ordered By: KAJAL SITWALA, MD, PhD
WX00000000002353

Printed D&T: 10/20/23 11:58

Kajal V. Sitwala, MD, PhD - Medical Director

Form: MM RL1

PAGE 3 OF 3